TÜRK, M. Et Al. 2018. Omalizumab treatment in atopic severe persistent asthma: A single center long-term real-life experience with thirty eight patients. Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , (Munich, Germany), 672.

TÜRK, M., Bahcecioglu, N. S., TUTAR, N., OYMAK, F. S., GÜLMEZ, İ., & YILMAZ, İ., (2018). Omalizumab treatment in atopic severe persistent asthma: A single center long-term real-life experience with thirty eight patients . Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) (pp.672). Munich, Germany

TÜRK, MURAT Et Al. "Omalizumab treatment in atopic severe persistent asthma: A single center long-term real-life experience with thirty eight patients," Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Munich, Germany, 2018

TÜRK, MURAT Et Al. "Omalizumab treatment in atopic severe persistent asthma: A single center long-term real-life experience with thirty eight patients." Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , Munich, Germany, pp.672, 2018

TÜRK, M. Et Al. (2018) . "Omalizumab treatment in atopic severe persistent asthma: A single center long-term real-life experience with thirty eight patients." Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , Munich, Germany, p.672.

@conferencepaper{conferencepaper, author={MURAT TÜRK Et Al. }, title={Omalizumab treatment in atopic severe persistent asthma: A single center long-term real-life experience with thirty eight patients}, congress name={Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI)}, city={Munich}, country={Germany}, year={2018}, pages={672} }